Formycon, a Germany-based biosimilar manufacturer, shared that its revenues for 2023 were 83% higher than in 2022, reaching a ...

Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine ...

Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network saved upwards of ...

Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that ...

Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to ...

On this episode of Not So Different, The Center for Biosimilars® discusses all the conference coverage, adalimumab data, and ...

Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop ...

Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the ...

A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars ...

Tyenne (tocilizumab-aazg) was the second tocilizumab biosimilar to be FDA approved, but it is the first to launch in the US.

Ha Kung Wong, JD, a patent attorney, explores the challenges of "patent thickets" in the biologics market, where a complex web of patents can hinder development of more affordable biosimilar drugs.

Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective ...